Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy

Antisense oligonucleotides (ASOs) have emerged as one of the most innovative new genetic drug modalities. However, their high molecular weight limits their bioavailability for otherwise-treatable neurological disorders. We investigated conjugation of ASOs to an antibody against the murine transferri...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammond, Suzan M., Abendroth, Frank, Goli, Larissa, Stoodley, Jessica, Burrell, Matthew, Thom, George, Gurrell, Ian, Ahlskog, Nina, Gait, Michael J., Wood, Matthew J.A., Webster, Carl I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614086/
https://www.ncbi.nlm.nih.gov/pubmed/36346674
http://dx.doi.org/10.1172/jci.insight.154142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614086/
https://www.ncbi.nlm.nih.gov/pubmed/36346674
http://dx.doi.org/10.1172/jci.insight.154142

Ejemplares similares